PMID- 10213503
OWN - NLM
STAT- MEDLINE
DCOM- 19990607
LR  - 20220408
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 8
DP  - 1999 Apr 15
TI  - Epidermal growth factor receptor blockade with C225 modulates proliferation, 
      apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.
PG  - 1935-40
AB  - We examined effects of the anti-epidermal growth factor receptor monoclonal 
      antibody C225 on proliferation, cell cycle phase distribution, apoptosis, and 
      radiosensitivity in squamous cell carcinoma (SCC) cell lines derived from head 
      and neck cancer patients. Exposure to C225 in culture inhibits SCC proliferation 
      in a time-dependent manner, and the degree of growth inhibition, compared to 
      controls, ranges from 20 to 75%. Flow cytometry analysis demonstrates that C225 
      treatment induces accumulation of cells in G1, which is accompanied by a 2-3-fold 
      decrease in the percentage of cells in S phase. C225 exposure also induces 
      apoptosis in SCC populations, as demonstrated by flow cytometry analysis using 
      dual stainings of merocyanine 540 and Hoechst 33342. Western blot analysis 
      indicates that C225 exposure induces accumulation of hypophosphorylated 
      retinoblastoma protein and increases expression of p27KIP1. An increase in Bax 
      expression and concurrent decrease in Bcl-2 expression are observed when SCC 
      cells are exposed to C225. Examination of C225 effects on radiation response in 
      SCCs demonstrates enhancement in radiosensitivity and amplification of 
      radiation-induced apoptosis. These effects are observed in both single-dose and 
      fractionated radiation experiments. C225 represents a promising growth-inhibitory 
      agent that can influence cellular proliferation, apoptosis, and radiosensitivity 
      in SCCs of the head and neck.
FAU - Huang, S M
AU  - Huang SM
AD  - Department of Human Oncology, University of Wisconsin School of Medicine and 
      Comprehensive Cancer Center, Madison 53792-0600, USA.
FAU - Bock, J M
AU  - Bock JM
FAU - Harari, P M
AU  - Harari PM
LA  - eng
GR  - CA 66786/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Antibodies, Monoclonal, Humanized
MH  - *Apoptosis
MH  - Carcinoma, Squamous Cell/*immunology/pathology
MH  - Cell Division/drug effects
MH  - Cell Survival/drug effects/radiation effects
MH  - Cetuximab
MH  - ErbB Receptors/*immunology
MH  - G1 Phase/drug effects
MH  - Head and Neck Neoplasms/*immunology/pathology
MH  - Humans
MH  - Radiation Tolerance/*drug effects
MH  - Resting Phase, Cell Cycle/drug effects
MH  - Tumor Cells, Cultured
EDAT- 1999/04/23 00:00
MHDA- 1999/04/23 00:01
CRDT- 1999/04/23 00:00
PHST- 1999/04/23 00:00 [pubmed]
PHST- 1999/04/23 00:01 [medline]
PHST- 1999/04/23 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Apr 15;59(8):1935-40.